Discovering the Real You: Personal Genomics

Would you like to know what is lurking in your genes?
Would you like to understand `nature vs. nurture' on a personal level?

Come join us for an evening discussion of Personal Genomics and how
it will impact the world we live in on at 7:00pm on November 5th at
950 Page Mill Rd., in Palo Alto.

Cost: $25 Pre-Registered, $35 at the door (cash or check only)
Location: Wilson Sonsini Goodrich and Rosati
950 Page Mill Road, Palo Alto

Register online: http://www.acteva.com/go/bioe2e

The cost of genetic testing has rapidly diminished, while our
understanding of the clinical impact of genetic differences has grown
exponentially. However, many questions remain:
• How can a company make a viable business in this space?
• What are the optimal ways to address genetic testing in
advance of defined clinical solutions?
• What is the value proposition for genetic testing?
• Will genetic testing drive clinical trial design?
• What stance has the FDA taken? Will it change?
• How can genetic testing be incorporated into our
dysfunctional healthcare system?
• Will genetic testing be reimbursed by insurance and Medicare
or will genetic testing remain a vanity for the rich?

Join BioE2E on November 5th to hear companies (Navigenics, 23andMe
and Pacific Biosciences) present their business strategies and
perspectives on genetic testing technology.

Speakers:

Stephen Moore, General Counsel, Navigenics
Mr. Moore was most recently associate general counsel with Affymetrix, Inc., a publicly traded biotechnology company developing advanced technologies for genetic screening. During his more than eight years at Affymetrix, he was responsible for a wide variety of strategic alliances, collaboration agreements and other transactional matters, including the spin-out of Perlegen Sciences, research collaborations with leading academic institutions such as the Broad Institute of MIT and Harvard, diagnostic product supply agreements and Affymetrix's Translational Medicine program in the United States and Canada.

Hugh Martin, Chairman and CEO, Pacific Bioscience
Mr. Martin joined Pacific Biosciences in 2004 as a seasoned executive with a 25-year track record managing leading edge technologies, new ventures, and high growth businesses. Previously, Mr. Martin was Chairman, President and CEO of ONI Systems—a high-speed optical telecommunications company he founded in 1998 and took public in 2000. Named the Fastest Growing Company in Silicon Valley in 2001, ONI was sold to Ciena in 2002. After its sale, Mr. Martin served as a consultant to Ciena, a CEO in residence at the venture capital firm of Kleiner Perkins Caufield and Byers, and was a Director at Cloudshield Technologies. Prior to ONI, Mr. Martin was President and Director of 3DO—an interactive gaming company. His earlier experience includes running desktop engineering for Apple Computer and founding Ridge Computers—designer of the world's first commercial reduced instruction set computing (RISC) minicomputer. Mr. Martin received a BS in Electrical Engineering at Rutgers University, New Brunswick, New Jersey. Mr. Martin currently serves on the Board of Directors of Pacific Biosciences and Infinera.

Vern Norviel, Partner at Wilson Sonsini Goodrich & Rosati
Mr. Norviel leads the patents and innovation counseling practice. Vern has more than two decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as personalized medicine, therapeutics, diagnostics, nanotechnology, genomics, proteomics, and cleantech.

Before joining the firm, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto.  During his career, Vern has authored or prosecuted more than 15 patents that have been litigated in the United States and abroad, and has overseen intellectual property lawsuits throughout the world.

Planned future events are on the Events Page